I'm LongbridgeAI, I can summarize articles.Hong Kong's 'other' sector reveals stark contrasts between state-backed resilience and governance fragility. China Taiping (0966.HK) secured regulatory approval for a HKD 7 billion capital injection—the first insurer 纳入 special treasury bond framework—though Q3 earnings face headwinds from equity market volatility. MicroPort Medical (0853.HK) remains suspended for seven weeks amid shareholder demands for an independent probe into its HKD 1.258 billion property lease transaction, with founder Chang Zhaohua's resignation amplifying concerns.
Gu Ming Tea (1364.HK) weathered a 11.4% intraday plunge after margin financing moves tied to tax payments, though Goldman Sachs maintained 'buy' citing 44.4% adjusted profit growth. Blocky (0325.HK) gained 4.03% weekly after debuting 500 new products at Wonder Festival Shanghai, outperforming despite broader weakness. Harbour BioMed (2142.HK) repurchased HKD 270 million over five days even as GIC trimmed stake to 7.95%.
New World Development (1686.HK) dropped 6.81% on weak data center sentiment, while CRRC Times Electric (3898.HK) secured rail contracts and attracted FIL Limited's 增持 to 5% stake. Jinyi Group (0565.HK) sold subsidiaries for nominal fees amid profit warnings, Free Gold (6228.HK) tumbled 12.88% on U.S. PPI data, and Perfect Medical (1830.HK) reshuffled its board. Operational transparency increasingly dictates survival in this fragmented landscape.
